Last reviewed · How we verify
NCT04762485
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
Phase 1, PHASE2 trial testing Humanized CD7 CAR-T cells in T Lymphoblastic Leukemia/Lymphoma in 20 participants. Status unknown.
28 February 2023
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 June 2021 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Humanized CD7 CAR-T cells — full drug profile →
Conditions studied
- T Lymphoblastic Leukemia/Lymphoma — all drugs for T Lymphoblastic Leukemia/Lymphoma →
- Mixed Phenotype Acute Leukemia — all drugs for Mixed Phenotype Acute Leukemia →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
Adults 12 to 65, any sex, with T Lymphoblastic Leukemia/Lymphoma or Mixed Phenotype Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective,open-label, single center and single arm phase 1/2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive acute leukemia.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w -
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, et al · · 2023 · cited 32× · PMID 37330575 · DOI 10.1186/s40364-023-00501-9 -
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. · · 2022 · cited 30× · PMID 35158765 · DOI 10.3390/cancers14030497 -
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia.
Cao X, Dai H, Cui Q, Li Z, et al · · 2022 · cited 29× · PMID 36175988 · DOI 10.1186/s40164-022-00318-6 -
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, et al · · 2023 · cited 28× · PMID 37168849 · DOI 10.3389/fimmu.2023.1152457 -
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C, Perna F. · · 2022 · cited 21× · PMID 36605213 · DOI 10.3389/fimmu.2022.1085978 -
Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W, Yang D, Chen X, Liang D, et al · · 2022 · cited 20× · PMID 36523990 · DOI 10.3389/fonc.2022.967754 -
Current state of CAR-T therapy for T-cell malignancies.
Luo L, Zhou X, Zhou L, Liang Z, et al · · 2022 · cited 19× · PMID 36601636 · DOI 10.1177/20406207221143025
Verify or expand the search:
- PubMed search for NCT04762485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Humanized CD7 CAR-T cells
Trials testing the same drug.
- NCT05059912 — CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma · Phase 2 · unknown
Other recruiting trials for T Lymphoblastic Leukemia/Lymphoma
Currently open trials in the same condition.
- NCT07153068 — SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies · Phase 1, PHASE2 · recruiting
- NCT07109518 — uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies · Phase 1 · recruiting
- NCT06712121 — Venetoclax and Decitabine in R/R T-ALL · Phase 2 · recruiting
- NCT05620680 — CD7 CAR-T Cells in T-cell Lymphoma/Leukemia · NA · recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04762485 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 2 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04762485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing